BMJ Open  Effectiveness and cost-effectiveness of a virtual community of practice to improve the empowerment of patients with ischaemic heart disease: study protocol of a randomised controlled trial

Ana Isabel González-González,1,2 Lilisbeth Perestelo-Pérez,3,4 Débora Koatz,5,6 Marta Ballester,5,6 Valeria Pacheco-Huergo,5,7 Vanesa Ramos-García,8 Alezandra Torres-Castaño,8 Amado Rivero-Santana,9,4 Ana Toledo-Chávarri,4,8 Cristina Valcárcel-Nazco,8 Juana Mateos-Rodilla,9 Juan Carlos Obaya-Rebollar,10 Javier García-García,11 Santiago Díaz-Sánchez,12 Luis Morales-Cobos,13 Josep Maria Bosch-Fontcuberta,14,15 Nuria Vallejo-Camazón,16 Ana Rodríguez-Almodovar,17 José Carlos del Castillo,18 Marcos Muñoz-Balsa,19 Yolanda del Rey-Granado,19 Sofía Garrido-Elustondo,20 María-Eugenia Tello-Bernabé,21 Ana Belén Ramírez-Puerta,19 Carola Orrego5,6

ABSTRACT

Introduction Virtual Communities of Practice (VCoP) or knowledge-sharing virtual communities offer ubiquitous access to information and exchange possibilities for people in similar situations, which might be especially valuable for the self-management of patients with chronic diseases. In view of the scarce evidence on the clinical and economic impact of these interventions on chronic conditions, we aim to evaluate the effectiveness and cost-effectiveness of a VCoP in the improvement of the activation and other patient empowerment measures in patients with ischaemic heart disease (IHD).

Methods and analysis A pragmatic randomised controlled trial will be performed in Catalonia, Madrid and Canary Islands, Spain. Two hundred and fifty patients with a recent diagnosis of IHD attending the participating centres will be selected and randomised to the intervention or control group. The intervention group will be offered participation for 12 months in a VCoP based on a gamified web 2.0 platform where there is interaction with other patients and a multidisciplinary professional team. Intervention and control groups will receive usual care. The primary outcome will be measured with the Patient Activation Measure questionnaire at baseline, 6, 12 and 18 months. Secondary outcomes will include: clinical variables; knowledge (Questionnaire of Cardiovascular Risk Factors), attitudes (Self-efficacy Managing Chronic Disease Scale), adherence to the Mediterranean diet (Mediterranean Diet Questionnaire), level of physical activity (International Physical Activity Questionnaire), depression (Patient Health Questionnaire), anxiety (Hospital Anxiety Scale-A), medication adherence (Adherence to Refill Medication Scale), quality of life (EQ-5D-5L) and health resources use. Data will be collected from self-reported questionnaires and electronic medical records.

Ethics and dissemination The trial was approved by Clinical Research Ethics Committee of Gregorio Marañón University Hospital in Madrid, Nuestra Señora de Candelaria University Hospital in Santa Cruz de Tenerife and IDIAP Jordi Gol in Barcelona. The results will be disseminated through workshops, policy briefs, peer-reviewed publications, local/international conferences.

Trial registration number ClinicalTrials.gov Registry (NCT03959631). Pre-results.

INTRODUCTION

In Western countries, ischaemic heart disease (IHD) is a major public concern,
and although mortality from IHD has been significantly reduced since 2000, it remains as a leading cause of death (50.6 deaths/100 000 inhabitants in Spain and 106.6 deaths/100 000 inhabitants in the USA in 2016).1 In Spain, 32 325 people died from IHD in 2017, according to the National Institute of Statistics.2 Patients with IHD may have a stable disease or an acute coronary syndrome, which could present with or without ST segment elevation. In addition, some patients may have left ventricular dysfunction and heart failure.3–5

For the treatment of IHD, in addition to the pharmacological treatment and, if necessary, interventional procedures, it is essential to manage cardiovascular risk factors such as smoking cessation, blood pressure, lipids and diabetes control, adherence to a Mediterranean diet, active lifestyle and prevent obesity. Moreover, for the secondary prevention of IHD, cardiac rehabilitation programmes are beneficial for patients, improving exercise capacity, quality of life and psychological well-being.6–8 The active role of the patient is crucial, along with the support of healthcare providers to achieve a successful secondary prevention of IHD.

The empowerment and self-management of patients with chronic conditions are becoming one of the main objectives in healthcare, especially in primary care (PC). The European EMPATHIE project9 defines the empowered patient as one who “has control over the management of the conditions of their daily life, actively tries to improve his/her quality of life and has the necessary knowledge, skills, attitudes and self-perception to adjust his/her behaviour and work in partnership with others when necessary, to achieve optimal well-being”.

One of the domains included in patient empowerment is the level of patient activation. Patient activation incorporates a combination of knowledge about the illness, ability and self-confidence in the management of the medical conditions.10 It is associated with healthy behaviours, good chronic disease metrics and reduced morbidity and unplanned hospitalisations.11–15

Interventions aimed at empowerment are intended to provide patients (and their informal caregivers, when appropriate) with the ability to participate in decisions related to their illness to the extent they wish, develop self-confidence, self-esteem and skills to face the physical, emotional and social impact of the disease in their daily lives.16–17

Virtual Communities of Practice (VCoP) offer ubiquitous access to information and exchange possibilities for people in similar situations, which is especially valuable in patients with chronic diseases. A CoP is a group of individuals who participate in a common activity and experience and create a shared identity and deepen their knowledge and experience in the area through a continuous interaction that strengthens their relationships.18 In this context, a group of patients with the same illness such as IHD, could benefit from an intervention of these characteristics where they can share resources and information in addition to having the possibility of receiving peer and professional support.

There is little research on the effect of VCoP in terms of their clinical and economic impact and on the empowerment of patients with chronic diseases, especially with IHD.19–20 We propose to address this gap and, thus, present the protocol of a randomised controlled trial, which mainly aims to evaluate the effectiveness and cost-effectiveness of a VCoP to improve the activation and other measures related with patient empowerment in patients with IHD.

METHODS AND ANALYSIS

This protocol has been prepared in accordance with the Standard Protocol Items: Recommendations for Interventional Trials checklist (online supplemental additional file 1).21

Study design

We plan a pragmatic randomised controlled multicentre trial (empodera²), with two parallel arms and 18-month follow-up.

Study setting

The setting of the intervention will be a virtual setting. Usual care will be provided at primary care practices (PCPs) and outpatient specialised clinics in Catalonia, Madrid and Canary Islands in Spain.

Eligibility criteria

Patients with a recent diagnosis of IHD will be screened for the following eligibility criteria:

Inclusion criteria

Age ≥18 years; active diagnosis in the electronic medical record (EMR) of IHD (International Classification of Primary Care Second Edition - ICPC-2 codes K74-76; or International Classification of Diseases 9th Edition - ICD-9 codes 410, 411, 411.8, 413, 414 and 414.9) in the year prior to inclusion in the study; internet at home or smartphone; be able to follow the requirements of the study (eg, digital literacy); have signed the informed consent (online supplemental additional file 2).

Exclusion criteria

Institutionalised, terminal illness, physical or mental disability that limits the ability to answer the questionnaires or when telephone/email contact is not available in the PCPs/hospitals’ databases.

Interventions

VCoP group

‘empodera²’ is a gamified VCoP on a web 2.0 platform based on the exchange of experiences and knowledge through participatory learning.22 It will provide educational, playful elements and tools that will facilitate the learning and transfer of knowledge and attitudes among patients with IHD and with healthcare professionals. The structure and components will be designed according to the needs and specifications of patients with IHD recruited.
in an earlier stage using a cocreation methodology with face-to-face sessions and virtual activities (forums and interactions) that incorporated a personalised itinerary—Patient Journey Map—(published elsewhere) and with the use of various types of content including readings, resources, videos, games and virtual sessions.22

Patients will have access to multidisciplinary professional support as needed and according to what was identified in the content-design stage (published elsewhere) that will potentially include general practitioners, cardiologists, psychologists, self-care and self-management specialists, nutritionist and others as necessary. Various thematic areas related to the empowerment of patients and self-care of IHD will be progressively covered: health competence, self-efficacy and activation improvement, behavioural changes, lifestyle/signs/symptoms monitoring, technical skills, chronic disease acceptance and shared decision-making. Special emphasis will be given to the changes recommended by European Guidelines23 for self-management of IHD including monitoring changes in symptoms, stress management, mental health and adherence to medication, diet, exercise plans, sodium cholesterol, and alcohol restriction and tobacco abstinence. The active role of a community manager, weekly emails as reminders and a gamified competitive score system will boost participation.

Usual care group
Patients allocated to both the intervention and the control group will continue with their usual self-care and professional care according to the local guidelines.3–5

Outcomes measures
Primary outcome
The primary outcome will be the patient activation level using the Patient Activation Measure (PAM) questionnaire that assesses activation in patients with chronic diseases.12 The questionnaire consists of 13 items that assess knowledge, skills and confidence of people for self-care, measured by a Likert 1–4 scale with a total score between 0 and 100 (100 identifies the patients with the highest level of activation). The Spanish translated version has been validated in patients with chronic diseases and has demonstrated a similar behaviour to the original instrument with good validity and reliability properties.24 It has been used in previous studies by this research team.25

Secondary outcomes
For the effectiveness of the VCoP, we will record the following secondary measures:
► Clinical variables such as body mass index, lipid profile (High-density lipoprotein cholesterol - HDL-C, Low-density lipoprotein cholesterol - LDL-C), smoking status, number and frequency of angina episodes will be collected through researcher developed online questionnaire that will be fulfilled by healthcare professionals combined with information from the EMR.
► Knowledge about the disease will be assessed through a self-administered online questionnaire based on the Questionnaire of Cardiovascular Risk Factors,26–28 previously translated from the English version and adapted to the Spanish population.
► Patients’ attitudes to self-care will be evaluated using the self-administered Self-efficacy Managing Chronic Disease Scale (SMCDS),29 translated into Spanish30 and used in patients with heart failure.31
► Adherence to the Mediterranean diet will be assessed with the Mediterranean diet questionnaire,32 translated and adapted to the Spanish language.30 Patients will be classified into three categories (low, medium and high) according to the index of physical activity (product of the intensity—in Metabolic Equivalents, METs—by the frequency) and the duration of the activity.
► Depressive disorders will be detected by the Patient Health Questionnaire-9 (PHQ-9),37 validated in Spanish with similar behaviour to the original and good acceptance.38
► Anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS scale),30 a 14-item questionnaire validated in PC in Spain40,41 with special interest and usefulness in the context of PC. It is a measure composed of two subscales (HADS-A: anxiety and HADS-D: depression), of 7 items each that are scored from 0 to 3. The authors recommend a threshold of eight points to detect possible cases of anxiety. One of the main virtues of this tool is the suppression of somatic symptoms. However, in patients with IHD, it underestimates people with depression,42 while the subscale HADS-A has good specificity and predictive value for measuring anxiety in this PC.43
► Adherence to medication will be assessed with the Adherence Refill and Medication Scale (ARMS),44 validated in Spain and used to measure adherence to medication in patients with chronic diseases. It consists of 12 questions and there is no cut-off point, the lower the score, the better the adherence. To quantify adherence, a value of 1–4 (never, sometimes, almost always or always) is assigned to each of the responses according to a Likert-type scale.
► Quality of life related to health (HRQoL) will be described and assessed with the EQ-5D-5L index,45,46 a generic and standardised instrument developed by the EuroQol Group, and prepared in several languages, including Spanish, and used in PC.47 It relates the HRQoL with the amount of life and offers a score for the gains in health, the Quality Adjusted Life Year (QALY). The descriptive EQ-5D-5L system comprises...
five dimensions (mobility, personal care, daily activities, pain/discomfort and anxiety/depression).

Explanatory and adjustment variables
Sociodemographic: age, sex, nationality, Autonomous Community of residence (Catalonia, Madrid or Canary Islands), marital status (married/partner, single, separated/divorced, widowed), living alone (yes/no), educational level (incomplete primary education, complete primary education, secondary education, university or equivalent studies), income level and employment status.

Morbidity-related: type of IHD (stable angina, unstable angina, myocardial infarction), duration of IHD (months), current diagnosis of heart failure in EMR (K86), left ventricular ejection fraction (≤30%, 30%–35%, 35%–45%, >45%), New York Heart Association (NYHA) functional classification (I–IV), number and description of chronic concomitant diseases, pharmacological treatment (acetylsalicylic acid or clopidogrel/ticagrelor/prasugrel, beta-blockers, statins, ACE inhibitors, angiotensin II receptor blockers, other treatments), cardiac catheterisation (yes/no) and participation in a cardiac rehabilitation programme before and during the study period (yes/no).

- Use of healthcare resources: primary care (PC) visits, visits to the emergency department, visits to specialists, number of hospitalisations, lengths of stay, prescribed medications, use of diagnostic tests.
- Loss of productivity: self-administered questionnaire about work absences related to the illness.
- Use of the VCoP: number of logins into the platform and time spent using the platform.

This information will be collected online from a patient self-reported questionnaire that the research team will elaborate combined with information from the EMR. VCoP use data will be collected through the platform database.

Adverse events
All significant adverse events as well as unintended consequences for each group will be collected and described by the site researcher, nominated for each PCP and hospital, and reported to the core team. A special form to report trial-related adverse events has been developed and distributed.

Participant timeline
Primary and secondary outcome measures will be collected before the start of the VCoP intervention and at 6, 12 and 18 months. See table 1.

Sample size
Assuming an alpha error of 0.05 and power of 80%, the necessary number of patients to detect, by means of independent two-sample t-test, an average minimal important difference of 4 points (SD 10) in the PAM questionnaire between the intervention and usual care group, is 200 patients (100 per arm). Assuming a 20% loss to follow-up, the required sample increases to 250 (125 per arm).

Recruitment
Patient recruitment will be organise on each Autonomous Community (Catalonia, Madrid or Canary Islands). The recruitment will be supported by informative meetings with directors and healthcare professionals (general practitioners, nurses, cardiologists) from the participating centres. In these meetings, a 10-minute presentation describing the study aim, planned time frame and tasks to be carried out by healthcare professionals, expected resources utilisation and funding procedures will be detailed. Patients that fulfil inclusion criteria will be actively encouraged by their healthcare professionals to participate by providing information about the trial and collecting their informed consent and contact details (eg, phone number/email). The research team will invite potential participants via phone and mail to access the ‘empodera’ platform where they will be provided with a unique registration code (figure 1). Patients will be consecutively included in the study; recruitment will be continuous until the sample size is reached.

Allocation and blinding
Two hundred and fifty patients will be randomly assigned to the intervention (VCoP) or control group. The randomisation, stratified by centre, will be central and automatically performed by the online ‘empodera’ platform and the assigned group will be communicated to the patient once he or she has entered the platform and completed baseline assessment (figure 1). Lack of knowledge of the randomisation sequence by the professionals who participate in the recruitment of patients will, therefore, be ensured. The intervention group will be taken directly to the registration page of ‘empodera’ VCoP, where they will receive a personalised message to welcome them into the platform. To warrant patient participation and cooperation, this type of intervention cannot be blinded to patients. Data analysis will be blinded to the assignment of the intervention.

Data management
In order to maintain participant confidentiality, all information will be stored with anonymised ID code numbers. The ID code numbers will be unrelated to participants’ identifiers, except in a central file with the participants’ contact details. All data will be stored on an electronic database management system located on a secure server with password-controlled access provided for research data collection. Databases will be designed to avoid downloading inappropriate values for every variable. Trial monitoring will be the responsibility of the core research team in charge of all quality control activities, assessing adherence to the trial protocol: timely work plan execution and comprehensiveness of data acquisition and data quality.
The Research Ethics Committees, the representatives of the Health Authority in matters of inspection and the personnel authorised by the Promoter, may only access to check personal data, clinical study procedures and compliance with the rules of good clinical practice (always maintaining the confidentiality of information).

Statistical analysis
Sociodemographic and clinical baseline variables for both groups will be analysed by descriptive methods (mean (SD), median (range), n (%)). The VCoP effect on the primary and secondary outcomes will be examined by means of multilevel linear regression, with the intervention, measurement time (0, 6, 12 and 18 months) and their interaction as fixed effects (along with other potential covariates), random intercepts for patients and general practitioner (GP), and unstructured covariance to account for within-subject correlations. We will also analyse the three-way interaction intervention×time×centre, since usual care could vary between centres, leading to differential intervention effects. We expect to recruit a sufficient number of GPs to allow their inclusion in the model as a random intercept, but we will perform a sensitivity analysis as well as excluding this component.

Between-group differences at each time-point will be compared by means of Wald’s $\chi^2$ test.

We will perform the analyses on an intention-to-treat basis (a sensitivity analysis on the per-protocol population will be also performed). Multiple imputation will be used for missing data, if applicable (Markov Chain Monte Carlo multivariate imputation algorithm, with 10 imputations per variable). Analyses will be carried out with the statistical software R V.4.0.2 (http://www.R-project.org/).

Cost-effectiveness analysis of the VCoP
We will carry out an economic evaluation, from baseline to 18-month follow-up, in which the costs and the results of the VCoP will be compared with the usual care following the recommendations of the guidelines for the management of patients with IHD, during the period of the clinical trial. The accepted analytical methods by the scientific community will be followed. The analysis will take both the perspective of the National Health System and of the social perspective. Therefore, direct healthcare costs and indirect costs will be included. The direct costs per patient will be calculated based on the use of healthcare resources, and the indirect costs will be estimated, focusing on productivity losses.
Selection of patients from selected centres belonging to Autonomous Communities of Catalonia, Madrid and Canary Island -Tenerife- (n=250)

Assessment of eligibility based on online inclusion/exclusion questions (age ≥ 18 years; active diagnosis in the electronic medical record (EMR) of IDH (ICPC-2 codes K74-76; or ICD-9 codes 410, 411, 411.8, 413, 414 y 414.9) in the year prior to inclusion in the study; Internet at home or Smartphone; be able to follow the requirements of the study)

Informed consent

Invitation to participate sent via Email

Potential participant visits trial website; trial information provided

Complete baseline assessment (t=0 weeks)

Confirm continued willingness to participate (t=1 week)

Randomization (t=1 week)

Allocated to Online Intervention Treatment: VCoP (n=125)

Completion of 6-month online VCoP follow-up assessment (n=?)

Completion of 12-month online VCoP follow-up assessment (n=?)

Completion of 18-month online VCoP follow-up assessment (n=?)

Allocated to Online Attention Control: Usual Care (n=125)

Completion of 6-month online follow-up assessment (n=?)

Completion of 12-month online follow-up assessment (n=?)

Completion of 18-month online follow-up assessment (n=?)

Loss to follow-up or discontinued (n=?)

Excluded: not active diagnosis in the electronic medical record (EMR) of IDH, not have Internet at home or Smartphone or not be able to follow the requirements of the study

Excluded: No informed consent

Outcomes: PAM, Sociodemographic and clinical variables, Knowledge, SMCDS, Mediterranean Diet Questionnaire, IPAQ, PHQ-9, HADS-A, ARMS, EQ-5D-5L

Figure 1 Flow of participants. ARMS, Adherence Refill and Medication Scale; CdPV, Comunidad de Práctica Virtual; HADS-A, Hospital Anxiety and Depression Scale; IPAQ, International Physical Activity Questionnaire; PAM, Patient Activation Measure; PHQ-9, Patient Health Questionnaire; SMCDS, Self-efficacy Managing Chronic Disease Scale.
due to IHD, applying the human capital approach. In addition to including the short-term costs (development and implementation of the VCoP), the costs observed during the follow-up will be included. We do not plan to consider opportunity costs in our cost-effectiveness analysis from the social perspective, as we understand that patients will use their free time on the VCoP and therefore they will not spend work or productive time not generating a cost for the system. The use of resources will be obtained from a patient self-reported questionnaire described in the outcome section. In addition, information about work absences related to the illness will be requested. The classic costs estimation approach will be followed, multiplying the use of resources by their unit cost. The unit costs will be obtained from the eHealth cost database (Oblikue Consulting) and from public sources such as rates and retail prize. The main outcome measure will be the incremental cost per gained QALY. The utilities for the estimation of the QALYs will be obtained through the EQ-5D-5L questionnaire that will be completed by the patient at the beginning of the study and at each follow-up visit. Results of the cost-effectiveness analysis will be summarised as the incremental cost-effectiveness ratio (ICER). ICER is the ratio of the differences in costs to the differences in observed effects. Non-parametric methods based on bootstrap simulations will be used to calculate CIs in the ICER. The same non-parametric methods will be used to calculate the acceptability curve that represents the probability that each choice will be cost-effective for different cost-effectiveness thresholds. The willingness-to-pay threshold is defined at Euro 25 000/QALY on the basis of the values most recently reported in the Spanish literature. Finally, deterministic sensitivity analyses (one, two or several ways) will be carried out in order to assess the impact of the parameters on the cost-effectiveness results of the VCoP.

**Patient and public involvement**

This protocol was developed without patient or public involvement. A group of patients with IHD will actively participate in a content-design previous stage using a cocreation methodology with face-to-face sessions and virtual activities.

**ETHICS AND DISSEMINATION**

Informed consent will be obtained from each participant before randomisation. The project received ethics approval from the local Committees at each participating Autonomous Community: Clinical Research Ethics Committee of Gregorio Marañón University Hospital in Madrid, Nuestra Señora de Candelaria University Hospital in Santa Cruz de Tenerife and from the coordinating centre IDIAP Jordi Gol in Barcelona (19/053-P). Patients will be personally informed by their physicians or nurses about the study and the possibility to participate during a programmed consultation. They will receive written information of the proposed research project, including information regarding the aims of the project, the duration of the participants’ involvement, the expected benefits to the participant and the procedures involved in the participation. Recruiters will emphasise that enrolment in the study is voluntary and that participants can withdraw at any moment of the project and that any decision they take in this respect will have no bearing on the medical care received. Once patients have signed the written informed consent, a researcher from the ‘empodera’ team will contact them via phone and/or mail to provide further information along with the necessary data (username and password) to login into the online platform. Additionally, recruiters will highlight that information generated by the study will be published, but no identification details will be divulged. Patients and healthcare providers will be informed of whom to contact in case of any query and research staff will be available to answer questions.

We will prepare presentations to disseminate the study findings to healthcare stakeholders and patients, and at relevant national and international conferences. We aim to publish the results of the trial in peer-reviewed journals.

**TRIAL STATUS**

The recruitment of patients in each region will start in September 2020. The estimated end date of the recruitment for this study is December 2020.

**Author affiliations**

1Goethe-Universitat Frankfurt am Main Institut fur Allgemeinmedizin, Frankfurt am Main, Hessen, Germany
2Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Gerencia Asistencial de Atención Primaria, Servicio Madrileño de Madrid, Madrid, Spain
3Servicio de Evaluación y Planificación del Servicio Canario de la Salud, Tenerife, Spain
4Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Tenerife, Spain
5Avedis Donabedian Research Institute (FAD), Barcelona, Spain
6Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Barcelona, Spain
7Centro de Atención Primaria Turó, Instituto Catalán de la Salud, Barcelona, Spain
8Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FISC), Tenerife, Spain
9Escuela Madrileña de Salud, Dirección General de Humanización y Atención al Paciente, Madrid, Spain
10Centro de Salud Chopera, Gerencia Asistencial de Atención Primaria, Madrid, Spain
11Unidad de Calidad y Seguridad del Paciente. Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain
12Centro de Salud Pintores, Gerencia Asistencial de Atención Primaria, Madrid, Spain
13Centro de Salud Las Américas, Gerencia Asistencial de Atención Primaria, Madrid, Spain
14Centro de Atención Primaria Encants, Instituto Catalán de la Salud, Barcelona, Spain
15Departament de Medicina Area de Medicina, Universitat Autonoma de Barcelona, Barcelona, Catalunya, Spain
16Hospital Germans Trias i Pujol, Badalona, Catalunya, Spain
17UGC Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
18Cardiovascular Area, Hospital San Juan de Dios, Tenerife, Canarias, Spain
REFERENCES

1. Wilkinson E, Wilson L, Wickramasinghe K, et al. European cardiovascular disease statistics. 192. 2017 edition. Brussels: Eur Hear Network, 2017.
2. Instituto Nacional de Estadística. Ine base. Available: http://www.ine.es/inenbusc/inemenu/index.htm#12 [Accessed 27 Feb 2018].
3. Ibáñez B, James S, Agewall S, et al. 2016 ESC Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting with ST-Segment Elevation. Eur Heart J 2018;39:119–77.
4. Knutsu J, Wijs W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–77.
5. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016;37:267–315.
6. García-Porrua E, Andrés-Esteban E, de Pablo-Zarzosa C, et al. Cardiologia preventiva Y rehabilitación. Revista Española de Cardiología 2010:63:40–8.
7. Piepoli MF, Corra L, Vendelle P, et al. Challenges in secondary prevention after acute myocardial infarction: a call for action. Eur J Prev Cardiol 2016;23:1994–2006.
8. Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016;CD018000.
9. EMPATHíE Consortium. EMPATHíE, empowering patients in the management of chronic diseases. final summary report 2014.
10. Hobbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff 2013;32:207–14.
11. Greene J, Hobbard JH. Why does patient activation matter? an examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med 2012;27:520–6.
12. Skoalsky RL, Green AF, Scharfstein D, et al. Psychometric properties of the patient activation measure among multimorbid older adults. Health Serv Res 2011;46:457–78.
13. Salyers MP, Matthias MS, Spann CL, et al. The role of patient activation in psychiatric visits. Psychiatr Serv 2009:60:1358–9.
14. Schmittidl J, Mosen DM, Glasgow RE, et al. Patient assessment of chronic illness care (PACIC) and improved patient-centered outcomes for chronic conditions. J Gen Intern Med 2008;23:77–80.
15. Mosen DM, Schmittidl J, Hobbard J, et al. Is patient association associated with outcomes of care for adults with chronic conditions? J Ambul Care Manage 2007;30:21–9.
16. Náfàrdi L, Nakamoto K, Schulz P, et al. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS One 2017;12:e0186458.
17. Rising T, Martínez J, Young J, et al. Evaluating patient Empowerment in association with eHealth technology: Scoping review. J Med Internet Res 2017;19:e329.
18. Li LC, Grimshaw JM, Nielsen C, et al. Evolution of Wenger’s concept of community of practice. Implement Sci 2009;4:11.
19. Oliva A. Psychosocial intervention 2013:22:15–23.
20. Pinilla J, Barber P, et al. El coste de la enfermedad potencialmente prevenible en España. Madrid; 2017.
21. Chan A-W, Tetlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586–7.
22. Bermejo-Caja CJ, Koatz D, Orrego C, et al. Acceptability and feasibility of a virtual community of practice to primary care professionals regarding patient empowerment: a qualitative pilot study. BMC Health Serv Res 2019;41:403.
23. National Clinical Guideline Centre. MI – Secondary Prevention: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction: Partial Update of NICE CG48. London Royal College of Physicians; 2013.
24. Moreno-Chico C, González-de Paz L, Montore-Foyo C, et al. Adaptation to European Spanish and psychometric properties of the patient activation measure 13 in patients with chronic diseases. Farn Pract 2017;34:627–34.
25. González-González AI, Orrego C, Perestelo-Pérez L, et al. Effectiveness of a virtual intervention for primary healthcare professionals aimed at improving attitudes towards the empowerment of patients with chronic diseases: study protocol for a cluster randomized controlled trial (e-MPODERA project). Trials 2017;18:505.
26. Alm-Rojer C, Stagmo M, Uddén G, et al. Better knowledge improves adherence to lifestyle changes and medication in patients with coronary heart disease. Eur J Cardiovasc Nurs 2004;3:321–30.
27. Alm-Rojer C, Fridlund B, Stagmo M, et al. Knowing your risk factors for coronary heart disease improves adherence to advice on lifestyle changes and medication. J Cardiovasc Nurs 2006;21:E24–31.
28. Saffi MAL, Jacques de Macedo Junior LJ, Tjoaah MM, et al. Validity and reliability of a questionnaire on knowledge of cardiovascular risk factors for use in Brazil. Rev Esc Enferm USP 2013:47:1083–9.
29. Lorí KR, Ritter PL. Hispanic chronic disease self-management. Nurs Res 2003;52:361–9.
30. Ritter PL, Lorí K. The English and Spanish self-efficacy to manage chronic disease scale measures were validated using multiple studies. J Clin Epidemiol 2014:67:1265–73.
31. Salvador-Hernández C, Cosculluela-Sires P, Blanes-Monllor C, et al. Insuficiencia cardíaca en atención primaria: actitudes, conocimientos y autocuidado. Atención Primaria 2018;50:213–21.
32. Trichopoulos A, Costacou T, Barnia C, et al. Adherence to a Mediterranean diet and survival in a Greek population. Eur J Epidemiol 2016;31:1083–9.
33. Martínez-González MA, García-Arellano A, Toledo E, et al. A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subjects: the PREDIMED trial. N Engl J Med 2012;366:2599–608.
34. Sánchez-Tainta A, Zapze I, Bes-Rastrollo M, et al. Nutritional adequacy according to carbohydrates and fat quality. Eur J Nutr 2015;50:93–100.
35. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279–90.
36. González-Arellano L, Toledo E, et al. Better knowledge improves adherence to lifestyle changes and medication in patients with coronary heart disease. Eur J Cardiovasc Nurs 2004;3:321–30.
37. Alm-Rojer C, Fridlund B, Stagmo M, et al. Knowing your risk factors for coronary heart disease improves adherence to advice on lifestyle changes and medication. J Cardiovasc Nurs 2006;21:E24–31.
38 Diez-Quevedo C, Rangil T, Sanchez-Planell L, et al. Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 General Hospital Spanish inpatients. *Psychosom Med* 2001;63:679–86.
39 Quintana JM, Padierna A, Esteban C, et al. Evaluation of the psychometric characteristics of the Spanish version of the hospital anxiety and depression scale. *Acta Psychiatr Scand* 2003;107:216–21.
40 Herrero MJ, Blanch J, Peri JM, et al. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. *Gen Hosp Psychiatry* 2003;25:277–83.
41 Terol-Cantero MC, Cabrera-Perona V, Martín-Aragón M. Revisión de estudios de la Escala de Ansiedad Y Depresión Hospitalaria (HAD) en muestras españolas. *An Psicol* 2015;31:494.
42 Morey JM, Bellwon J, Adamczyk K, et al. Depression and anxiety in patients with coronary artery disease, measured by means of self-report measures and clinician-rated instrument. *Kardiol Pol* 2016;74:53–60.
43 Bunevicius A, Staniute M, Brozaitiene J, et al. Screening for anxiety disorders in patients with coronary artery disease. *Health Qual Life Outcomes* 2013;11:37.
44 González-Bueno J, Calvo-Cidoncha E, Sevilla-Sánchez D, et al. [Spanish translation and cross-cultural adaptation of the ARMS-scale for measuring medication adherence in polypathological patients]. *Aten Primaria* 2017;49:459–64.
45 Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727–36.
46 Ramos-Góñi JM, Craig BM, Oppe M, et al. Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach. *Value Health* 2018;21:596–604.
47 Herdman M, Badia X, Berra S. El EuroQol-5D: Una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. *Atención Primaria* 2001;28:425–9.
48 Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic status and cardiovascular outcomes. *Circulation* 2018;137:2166–78.
49 O’Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. *Fam Pract* 2004;21:381–6.
50 Glick H, Doshi J, Sonnad S, et al. *Economic evaluation in clinical trials*. 1st ed. Oxford: Oxford University Press, 2007.
51 Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. *Health Econ* 2018;27:746–61.